16
total announcements
INDRANIB.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹38 Cr
P/E (TTM)
20.7
EPS (TTM)
₹0.40
52W Low
₹6.10
52W High
₹16.47
Dividend Yield
0.00%
Beta
0.19
Price / Book
0.5
Debt / Equity
125.7
Revenue (TTM)
₹146 Cr
Gross Margin
28.05%
Operating Margin
0.99%
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced the resignation of Mr. K.S. Vaidyanathan, an Independent Director, due to personal reasons, effective October 13, 2026. The Board has accepted his resignation and he will be relieved from his position.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the acceptance or rejection of dematerialized securities and listing of securities on stock exchanges.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a limited review report. The company's board of directors has approved the reconstitution of audit, stakeholder relationship, and rights issue committees. The statutory auditors have reviewed the financial results and given an unmodified opinion.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a limited review report. The company's board of directors has approved the reconstitution of the audit committee, stakeholder relationship committee, and rights issue committee. The statutory auditors have reviewed the financial results and given an unmodified opinion.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has scheduled a Board Meeting on 07/10/2026 to consider unaudited financial results for Q2 2026 and reconstitute various Board Committees.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced the closure of its trading window for the quarter and half year ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The company will declare its unaudited financial statements for the period in due course.
Indrayani Biotech Limited
Indrayani Biotech Limited has informed BSE about the appointment of a new Company Secretary.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced a Letter of Offer for a Rights Issue of up to 3,25,25,897 partly paid-up equity shares at ₹15 per share, with an aggregate amount not exceeding ₹4878.88 Lakhs.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has revised the schedule of its partly paid-up Rights Issue, extending the opening date to September 15, 2026, and closing date to October 14, 2026, with the last date for on-market renunciation revised to October 8, 2026.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has appointed Mr. C.S. Shanmuga Sundar as its company secretary and compliance officer, effective September 9, 2026.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has published its audited financial results for the quarter and year ended March 31, 2026, in accordance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited financial results for the quarter and year ended March 31, 2026, along with the report of the statutory auditors. The auditors have issued a qualified opinion due to certain matters, including unconfirmed trade creditor balances and non-compliance with Indian Accounting Standards (IND AS) for certain subsidiaries.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended 31st March 2026. The results have been approved by the Board of Directors, but the consolidated figures have not been subjected to audit/review. The auditor's report includes a qualified opinion due to certain issues with trade creditors and subsidiaries.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditor's report. The results will be published in newspapers and will also be available on the company's website and the BSE website.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 17/08/2026 to consider and approve audited financial statements for the Quarter and Financial Year ended March 31, 2026, along with notes thereon and to authorise directors to sign the same.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced the indefinite postponement of its partly paid-up Rights Issue. The Rights Issue Committee, at its meeting on June 22, 2026, decided to defer the schedule until further notice, which was previously extended to close on July 24, 2026. While the revised opening and closing dates will be intimated later, the offer price and rights entitlement ratio approved earlier will remain unchanged.